Pregnancy-Associated Acute Respiratory Failure in ICU: Clinical Considerations and Evidence-Based Management

Abstract

Acute respiratory failure (ARF) during pregnancy is a rare but critical condition with significant maternal and fetal morbidity and mortality. The unique physiological adaptations in pregnancy, combined with diverse etiologies, present diagnostic and therapeutic challenges in the intensive care unit (ICU). This review synthesizes current evidence on epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, management strategies, and recent advances in the care of pregnant patients presenting with ARF. Emphasis is placed on guideline-directed management, multidisciplinary coordination, and the integration of emerging therapies for optimal outcomes.

Introduction

Acute respiratory failure is defined by the inability of the respiratory system to maintain adequate gas exchange, resulting in hypoxemia, hypercapnia, or both. In pregnancy, the interplay between physiological changes and pathological insults can rapidly precipitate respiratory compromise. Management is further complicated by the need to ensure maternal as well as fetal well-being, and to balance maternal resuscitation with considerations such as teratogenicity and uterine perfusion. With the increase in maternal age, comorbidities, and high-risk pregnancies, intensive care physicians are encountering ARF in pregnancy more frequently. This review aims to provide clinicians with a comprehensive, evidence-based guide to understanding and managing this challenging condition in the ICU setting.

Epidemiology / Disease Burden

Pregnancy-associated ARF is uncommon, affecting approximately 1 in 1,000 pregnancies, but accounts for a disproportionate share of obstetric ICU admissions and maternal mortality. The incidence varies globally, with higher rates reported in regions with limited access to antenatal care and critical care resources. Maternal mortality from ARF ranges from 10–30%, with fetal mortality rates often higher, particularly in cases requiring mechanical ventilation. Common etiologies include pneumonia (bacterial, viral, and aspiration), preeclampsia/eclampsia, pulmonary edema, thromboembolism, amniotic fluid embolism, and acute asthma exacerbations. Emerging viral epidemics, such as COVID-19, have further underscored the vulnerability of pregnant women to severe respiratory illness.

Pathophysiology

Pregnancy induces profound changes in respiratory physiology, including increased minute ventilation, decreased functional residual capacity, and elevated oxygen consumption. These adaptations lower maternal respiratory reserve, rendering pregnant women more susceptible to hypoxemia during pulmonary insults. Hormonal influences lead to airway mucosal edema, and the upward displacement of the diaphragm by the gravid uterus further restricts lung expansion. The immunological milieu of pregnancy, characterized by shifts in cell-mediated and humoral immunity, may also predispose to infectious causes of ARF. In the context of preeclampsia or sepsis, endothelial dysfunction, capillary leak, and non-cardiogenic pulmonary edema are critical mechanisms contributing to respiratory compromise.

Risk Factors

Risk factors for pregnancy-associated ARF include advanced maternal age, obesity, pre-existing cardiopulmonary disease, multifetal gestation, hypertensive disorders of pregnancy, immunosuppression, and substance use (e.g., tobacco, illicit drugs). Iatrogenic factors, such as excessive fluid administration or transfusion, may precipitate or exacerbate ARF. Certain obstetric complications, including chorioamnionitis, postpartum hemorrhage, and anesthesia-related adverse events, further increase the risk. Epidemiological studies also highlight racial and socioeconomic disparities in the incidence and outcomes of ARF in pregnancy, underscoring the need for targeted preventive strategies.

Clinical Features

The clinical presentation of ARF in pregnancy ranges from subtle dyspnea and tachypnea to overt respiratory distress, cyanosis, and altered mental status. Signs such as accessory muscle use, tachycardia, hypotension, and decreased oxygen saturation warrant immediate attention. The underlying etiology often influences the clinical picture: pneumonia may present with fever and productive cough; pulmonary embolism with sudden onset pleuritic chest pain and hemoptysis; preeclampsia-associated pulmonary edema with hypertension and proteinuria. Fetal compromise may manifest as decreased fetal movements or abnormal heart rate patterns, necessitating continuous fetal monitoring in viable gestations. Early recognition of clinical deterioration is critical for timely escalation of care.

Diagnosis

Diagnostic evaluation involves rapid assessment of airway, breathing, and circulation, followed by targeted investigations to elucidate the cause of ARF. Arterial blood gas analysis is essential for quantifying hypoxemia and hypercapnia. Chest imaging (preferably low-radiation dose chest X-ray or ultrasound) is often required, with computed tomography angiography reserved for suspected pulmonary embolism. Laboratory tests include complete blood count, inflammatory markers, renal and hepatic function, and microbiological cultures. Bedside echocardiography may assist in distinguishing cardiogenic from non-cardiogenic pulmonary edema. Fetal assessment by cardiotocography is recommended for pregnancies beyond viability. Diagnostic strategies must balance maternal benefit with minimization of fetal radiation exposure and teratogenic risk.

Treatment & Management

Management of ARF in pregnancy centers on optimizing maternal oxygenation and ventilation, while minimizing fetal risk. Supplemental oxygen should be administered to maintain maternal saturation above 95%. Non-invasive ventilation (NIV) may be trialed in select cases, though intubation and invasive mechanical ventilation are often required for severe hypoxemia or airway compromise. Lung-protective ventilation strategies, with low tidal volumes and permissive hypercapnia, are advocated to reduce ventilator-induced lung injury. Prone positioning, though challenging in late pregnancy, is feasible with appropriate support and has demonstrated benefit in refractory ARDS. Fluid management should be conservative to avoid pulmonary edema, and vasopressors may be required for hemodynamic support. Definitive management of the underlying cause antibiotics for infection, anticoagulation for thromboembolism, magnesium sulfate for eclampsia is critical. Multidisciplinary collaboration with obstetricians, neonatologists, and anesthesiologists is paramount.

Recent Advances / Emerging Therapies

Recent years have witnessed advances in the supportive care of pregnant women with ARF. High-flow nasal cannula and extracorporeal membrane oxygenation (ECMO) have emerged as rescue therapies in severe cases unresponsive to conventional ventilation. Antiviral and immunomodulatory therapies, particularly in the context of COVID-19, have been used with increasing frequency, though safety data in pregnancy remain limited. Enhanced bedside monitoring, advances in point-of-care ultrasound, and protocol-driven sepsis management have improved early identification and outcomes. Research is ongoing into the utility of biomarkers and genomics for risk stratification and individualized therapy.

Guideline Recommendations

Current guidelines emphasize early recognition, prompt ICU admission, and aggressive supportive care for pregnant women with ARF. The Surviving Sepsis Campaign and ARDS Network protocols provide a framework for ventilatory and hemodynamic management, with modifications for pregnancy as needed. Obstetric and critical care societies advocate for multidisciplinary care, individualized risk assessment, and ongoing fetal surveillance. Delivery is indicated only for obstetric indications or refractory maternal compromise, and timing should be individualized based on gestational age, maternal status, and fetal well-being. Pre-delivery corticosteroids for fetal lung maturity are recommended if imminent preterm birth is anticipated.

Conclusion

Pregnancy-associated acute respiratory failure remains a formidable clinical challenge, necessitating a nuanced understanding of maternal and fetal physiology, disease mechanisms, and evidence-based interventions. Early recognition, rapid diagnosis, and guideline-driven management are essential for optimizing outcomes. Ongoing research, advances in supportive technologies, and multidisciplinary collaboration will continue to shape the care of these high-risk patients in the ICU. Vigilance, clinical acumen, and a patient-centered approach remain the cornerstones of successful management.